(NASDAQ: ARDX) Ardelyx's forecast annual revenue growth rate of 21.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.51%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.32%.
Ardelyx's revenue in 2026 is $468,220,000.On average, 13 Wall Street analysts forecast ARDX's revenue for 2026 to be $123,642,617,644, with the lowest ARDX revenue forecast at $116,491,068,511, and the highest ARDX revenue forecast at $129,740,915,780. On average, 13 Wall Street analysts forecast ARDX's revenue for 2027 to be $155,896,229,920, with the lowest ARDX revenue forecast at $135,612,978,618, and the highest ARDX revenue forecast at $179,090,375,385.
In 2028, ARDX is forecast to generate $210,635,117,061 in revenue, with the lowest revenue forecast at $160,119,288,810 and the highest revenue forecast at $241,169,341,074.